FDA Inspection 1001337 — Central Jersey Blood Center
The FDA completed an inspection of Central Jersey Blood Center on Jan 27, 2017 in Howell, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 27, 2017
- Fiscal Year
- 2017
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Howell, NJ (United States)